Based on these considerations, glucagon could be a potential molecule to counteract obesity through the activation of EE and BAT, even though the well-known hyperglycaemic excursions associated with this hormone [214] make it potentially harmful if used as a monotherapy for obese subjects with impaired glucose regulation. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.